Alexandra Kitz
Messenger RNACancerInternal medicineOncologyResidualProstateLungProgressive diseaseNeuroendocrine tumorsDiseaseLiquid biopsyProstate cancerTumor recurrenceCancer researchColorectal cancerMedicineBiomarker (medicine)Chromogranin ABiologyGastroenterology
13Publications
2H-index
6Citations
Publications 13
Newest
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Alexandra KitzH-Index: 2
view all 0 authors...
INTRODUCTION Identification of residual disease after neuroendocrine tumor (NET) resection is critical for management. Post-surgery imaging is insensitive, expensive and current biomarkers ineffective. We evaluated whether the NETest, a multigene liquid biopsy blood biomarker, correlated with surgical resection and could predict recurrence. METHODS Multicenter evaluation of NET resections over 24 months (n=103): 47 pancreas, 26 small bowel, 26 lung, 2 appendix, 1 duodenum, 1 stomach. Surgery: R0...
Source
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Alexandra KitzH-Index: 2
view all 17 authors...
Introduction Surgery is the only cure for neuroendocrine tumors (NETs), with R0 resection being critical for successful tumor removal. Early detection of residual disease is key for optimal management, but both imaging and current biomarkers are ineffective post-surgery. NETest, a multigene blood biomarker, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scores post-surgery would predict recurrence. Methods This was a multicenter ev...
3 CitationsSource
Abstract Biomarkers that are secretory monoanalyte products of GEP (gastro-entero-pancreatic) and BP (broncho-pulmonary) or lung NETs (neuroendocrine tumors) have significant limitations in clinical utility. The assessment of secretory activity provides little information in regard to tumor biology. Furthermore, ∼50% of NETs have measurable secretory products. Molecular genomic identification in blood (NETest liquid biopsy) of the regulators of tumor biology provide multianalyte, real-time asses...
Source
#1Mark KiddH-Index: 5
#1Mark KiddH-Index: 66
Last. Irvin M. ModlinH-Index: 81
view all 4 authors...
BACKGROUND: The NETest is a multi-gene assay comprising 51 circulating neuroendocrine tumor specific transcripts. The quotient of the 51-gene assay is based upon an ensemble of machine learning algorithms. Eight cancer hallmarks or "omes" (apoptome, epigenome, growth factor signalome, metabolome, proliferome, plurome, secretome SSTRome) represent 29 genes. The NETest is an accurate diagnostic (>90%) but its prognostic utility has not been assessed. In this study, we describe expansion of the NET...
2 CitationsSource
#1Mark KiddH-Index: 4
#2Alexandra KitzH-Index: 2
Last. Irvin M. ModlinH-Index: 11
view all 4 authors...
Source
#1Irvin M. ModlinH-Index: 11
#2Mark KiddH-Index: 4
Last. Faidon-Marios LaskaratosH-Index: 7
view all 17 authors...
Source
Source
#1Kambiz RahbarH-Index: 22
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 9 authors...
Background: There are a paucity of blood-based biomarkers with clinical utility for prostate cancer (PCa). We examined a circulating-free mRNA (27-gene) prostate cancer signature to diagnose PCa. Clinical utility of the assay was then assessed in surgical patients. Methods:Gene identification and validation: Publicly available PCa transcriptome sets (n=5) (E-GEOD-46691, E-GEOD-46602, E-GEOD-62116, E-GEOD-62667, E-GEOD-72220: n=1,159 samples); PCA cell lines (n=7) gene expression in 22Rv1 and E00...
Source
#1Kambiz RahbarH-Index: 22
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 9 authors...
Background: Neuroendocrine differentiation and the development of an aggressive phenotype are key features of castration-resistant prostate cancer (CRPC) disease. Current blood-based biomarkers cannot detect these treatment-refractory cancer variants. Aims: Evaluate the utility of the NETest, a blood-based 51-marker gene neuroendocrine detection tool, as a CRPC diagnostic and examine which functional gene clusters (hallmarks) differentiate CRPC from PCa. Methods:NETest gene identification in CRP...
Source
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Harry R. Aslanian (Yale University)H-Index: 28
view all 7 authors...
e16079Background: There are few blood-based biomarkers for colorectal cancer (CRC). We report a 13-gene colon cancer circulating-free mRNA to diagnose CRC. Clinical utility was assessed in surgical...
Source